[Expert consensus on the out-of-hospital management of myelosuppression associated with oncological treatment (2025 edition)].

Myelosuppression is a common hematological side effect of oncological treatment, mainly including neutropenia, thrombocytopenia and anemia. Due to the delay in its clinical manifestation, a well-established out-of-hospital management system can help clinicians better prevent and manage the myelosuppression associated with oncology treatment and ensure the effectiveness and safety of antitumor therapy. This consensus focuses on a detailed compilation and summary of the definition and grading of myelosuppression associated with oncological treatment, the principles of out-of-hospital management, the management process and management methods, develops a risk stratification assessment table for oncology treatment-related myelosuppression, and puts forward 8 recommendations based on the risk stratification, which is aimed at providing medical workers with a reference plan for the out-of-hospital management of myelosuppression associated with oncological treatment.